5:18 PM
 | 
Mar 12, 2012
 |  BC Extra  |  Clinical News

Basilea's Toctino meets eczema endpoint

Basilea Pharmaceutica AG (SIX:BSLN) said once-daily oral Toctino alitretinoin for up to six months met the primary endpoint of a greater proportion of patients achieving "clear" or "almost clear"...

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >